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Abstract
Trip6 is a member of a subfamily of LIM domain proteins, including also zyxin, LPP, Ajuba, and Hic-5, which localize
primarily to focal adhesion plaques. However, in this report, we demonstrate that Trip6 is largely in the nucleus in cells
treated with leptomycin B, suggesting that Trip6 shuttles between nuclear and cytoplasmic compartments and that nuclear
export of Trip6 is dependent on Crm1. Consistent with this finding, we have identified a nuclear export signal (NES) in
Trip6, and mutation of this NES also results in sequestration of Trip6 in the nucleus. Addition of the Trip6 NES to the
nuclear v-Rel oncoprotein redirects v-Rel to the cytoplasm. Trip6 also has at least two sequences that can direct cytoplasmic
L-galactosidase to the nucleus. Using GAL4 fusion proteins and reporter gene assays, we demonstrate that Trip6 has multiple
transactivation domains, including one that appears to overlap with sequences of the NES. In vitro- or in vivo-synthesized
Trip6, however, does not bind to DNA^cellulose. Taken together, these results are consistent with Trip6, and other members
of this LIM protein family, having a role in relaying signals between focal adhesion plaques and the nucleus. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
LIM domains are thought to be primarily protein^
protein interaction domains [1,2]. Trip6 is a LIM
domain-containing protein that is part of a subfamily
of LIM domain proteins that also includes zyxin,
lipoma preferred partner (LPP), Ajuba, paxillin,
and Hic-5, among others [1,2]. These proteins con-
tain three or more copies of highly related LIM do-
mains towards their C-termini.
The exact functions of members of this subfamily
of LIM domain proteins are not known. In resting
cells, most proteins in this family primarily reside in
focal adhesion plaques, but under a variety of cir-
cumstances several can also enter the nucleus [3^8].
Moreover, LPP and Trip6 have sequences that can
activate transcription [5^7], and Hic-5 can bind DNA
through its LIM domain sequences [3]. Zyxin and
LPP have been shown to interact with several focal
adhesion plaque proteins, including Ena/VASP
[5,9,10]. In addition, Trip6 has been identi¢ed as in-
teracting with a variety of nuclear (thyroid hormone
receptor [11] and v-Rel [7]) and cytoplasmic (protein
phosphatase PTP1E and PTPBL [12,13]) proteins.
Taken together, these results suggest that these
LIM proteins have distinct nuclear and adhesion
plaque functions, and may relay signals between fo-
cal adhesion plaques and the nucleus.
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In this report, we have further investigated the
requirements for nuclear activities of Trip6. Our re-
sults demonstrate that Trip6 appears to shuttle be-
tween cytoplasmic and nuclear compartments, due to
a nuclear export signal (NES) towards its N-terminus
and nuclear targeting functions in both N-terminal
sequences and in C-terminal sequences that include
the LIM domains. We also show that Trip6 has mul-
tiple transactivation domains, including one that ap-
pears to overlap with the NES.
2. Materials and methods
2.1. Recombinant DNA techniques and plasmid
constructions
Recombinant DNA techniques were generally per-
formed as described [14]. Site-directed mutagenesis of
the NES of Trip6 was performed by PCR using the
following oligonucleotides as the mutagenic primers
and pcDNA-FLAG-Trip6 [6] as template: 5P-CA-
TCAGCCGCCATGCTGGTGGCCGAATCTATC-
TC-3P (triple-mutation primer 1) or 5P-GATCAG-
CCGCCATGCTGGTGGCCGAATCTATCTC-3P
(double-mutation primer 1) or a Trip6-speci¢c prim-
er (for single mutation) and T7 promoter primer to
generate 5P NES/mutant PCR product; 5P-AGA-
TTCGGCCACCAGCATGGCGGCTGATGCGGA-
CGGGGGT-3P (triple-mutation primer 2) or 5P-AG-
ATTCGGCCACCAGCATGGCGGCTGATCTGG-
ACG-3P (double-mutation primer 2) or 5P-GAT-
TCGCTCACCAGCATGTTGGCTGATGCGGAC-
GGGGGTCGC-3P (single-mutation primer 2) and a
downstream Trip6-speci¢c primer to generate 3P
NES/mutant PCR product. After digestion of the
NES/mutant PCR products with EcoRI/BstXI and
the 3P NES/mutant PCR products with BstXI and
SacII, these two fragments were simultaneously sub-
cloned into pcDNA-FLAG-Trip6, which had been
digested with EcoRI and SacII.
Retroviral vectors for the expression of v-Rel,
v-dStu/Hinc, and TGV have been described previ-
ously [15]. To create plasmids v-Rel-NES and
v-Rel-NES-mutant, primers were used to amplify
the NES-containing region of wild-type and NES-
mutant Trip6. The fragments were then digested
with StuI and HincII, which digested within the de-
signed primers, and the fragments were used to re-
place a 120 bp fragment of v-rel between unique StuI
and HincII sites [15]. The recombinant v-rel-trip6/
NES chimeric genes were then subcloned as XbaI
fragments into the corresponding site of spleen ne-
crosis virus vector JD214BS+ [16].
To create a plasmid for the expression of L-galac-
tosidase (L-gal), the lacZ gene with 5P sequences of
the CAT gene was digested by HindIII and DraI in
plasmid RSV-L-gal [15], and this fragment was sub-
cloned into HindIII/EcoRV-digested pcDNA3.1(+).
To create plasmids expressing the L-gal-LIM and
L-gal-vLIM fusion proteins, a C-terminal fragment
or the N-terminal region was generated by ScaI/XbaI
or HpaI/XbaI digestion of pcDNA-FLAG-Trip6, re-
spectively, and these fragments were then ligated to
lacZ (in-frame) in pcDNA3.1-L-gal that had been
treated with BlpI/Klenow and XbaI. To create
pcDNA3.1-L-gal-vLIM/NES mutant, the KpnI/
BspEI fragment from pcDNA3-Trip6/NES mutant
was subcloned into pcDNA3.1-L-gal treated by
KpnI/BspEI. All subclones were con¢rmed by DNA
sequencing and in vitro translation.
The GAL4 producer plasmid SG424 and GAL4^
Trip6 producer plasmid SG-MoTrip6 (GAL4-vN-
Trip6-1) have been described previously [6,17].
pcDNA-FLAG-Trip6-LIM and pcDNA-FLAG-
Trip6-vLIM were produced by EcoRI/Klenow and
ScaI or NotI/Klenow and ScaI digestion of
pcDNA-FLAG-Trip6, respectively, and the vector
backbones were then religated. GAL4^Trip6,
GAL4^Trip6-LIM and GAL4^Trip6-vLIM were
then created by subcloning HpaI and XbaI fragments
from corresponding pcDNA-FLAG plasmids (de-
scribed above) into pSG424 that had been treated
with KpnI/T4-DNA-polymerase and XbaI. GAL4-
vN-Trip6-2 was made by subcloning an EcoRI/Kle-
now- and XbaI-treated fragment from pcDNA-
FLAG-vN-Trip6 [6] into pSG424 that had been
treated with BamHI/Klenow and XbaI. To create
pcDNA-FLAG-vN-Trip6-3, an NcoI/Klenow-treated
to NotI fragment of a mouse Trip6 cDNA was sub-
cloned into pcDNA-FLAG that had been digested
with BamHI, treated with Klenow and then digested
with NotI. GAL4-vN-Trip6-3 was then made by sub-
cloning a BamHI/XbaI-digested fragment from
pcDNA-FLAG-vN-Trip6-3 into the corresponding
sites of pSG424. All pSG-Trip6/NES-mutants were
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created by subcloning KpnI/XbaI fragments from the
given pcDNA-Trip6/NES mutants into pSG-Trip6
that had been digested with KpnI and XbaI. Plasmid
SG-zyxin was created by subcloning a fragment con-
taining codons 1^572 of human zyxin into pSG424
that had been treated with KpnI/Klenow/XbaI. All
subclones that involved blunt-end ligations were con-
¢rmed by DNA sequencing.
2.2. Cell culture, GAL4-site reporter gene assays,
and indirect immuno£uorescence
Chicken embryo ¢broblasts (CEF) were obtained
from Spafas, Inc. and were cultured in Dulbecco’s
modi¢ed Eagle’s medium containing 10% fetal calf
serum. Where indicated, leptomycin B (a kind gift
of Minoru Yoshida) was added at 20 ng/ml.
GAL4-site CAT reporter gene assays were performed
as described previously [6]. Indirect immuno£uores-
cence on transfected cells was performed by ¢xing
cells in paraformaldehyde and using primary antise-
rum against FLAG, L-gal, or GAL4 as described
previously [6,15,18]. Detection of antigens with £uo-
rescein-conjugated secondary antibody and DAPI
staining were also performed as described previously
[6].
2.3. DNA-binding assays
Coupled in vitro transcription/translation was per-
formed in wheat germ extract or rabbit reticulocyte
lysate in the presence of Tran35S-label (Amersham)
according to the manufacturer’s (Promega) recom-
mendations as described previously [6]. FLAG epi-
tope-tagged full-length Trip6 and N-terminally trun-
cated Trip6(vN) were translated in vitro from
pcDNA-FLAG-Trip6 and pcDNA-FLAG-vN-
Trip6, respectively. Trip6, c-Src, v-Rel and v-Rel mu-
tant (v-dStu/Hinc) were translated in vitro from
pGEM4-MoTrip6, pGEM4-c-Src, CG129 and
CG129/dStu/Hinc expression plasmids, respectively,
which have been described previously [6,19]. Dou-
ble-stranded DNA^cellulose (USB Corporation;
80 mg/ml) was preincubated in BD bu¡er (0.2 M
NaCl, 50 mM Tris, pH 7.5, 0.2 mM ZnCl2, 0.2%
(v/v) Triton X-100, 5% (v/v) glycerol, 2 mg/ml
BSA) at 4‡C overnight, and 50 Wl DNA^cellulose
was then incubated with 5^10 Wl of in vitro-trans-
lated proteins in BD bu¡er at room temperature
for 2 h, washed once with BD bu¡er brie£y, twice
with wash bu¡er (0.3 M NaCl, 50 mM Tris, pH 7.5,
0.2 mM ZnCl2, 1% Triton X-100, 0.1% SDS, 5%
glycerol) for 10 min each at room temperature.
DNA^cellulose beads were pelleted and boiled in
2USDS sample bu¡er (0.125 M Tris, pH 6.8, 4.6%
SDS, 20% glycerol, 10% L-mercaptoethanol, 0.2%
bromophenol blue) at 95^100‡C for 20 min. The
supernatant was then loaded on a 12.5% SDS-poly-
acrylamide gel, and proteins were detected using a
Molecular imager (Bio-Rad). Two microliters of in
vitro-translated proteins were loaded on a parallel gel
as a control.
Fig. 1. Treatment of cells with leptomycin B causes Trip6 to accumulate in the nucleus. CEF were transfected with a FLAG-Trip6
expression vector and were analyzed by indirect immuno£uorescence using an anti-FLAG primary antibody. (A) Untreated CEF.
(B) CEF treated with leptomycin B for 15 min. (C) CEF treated with leptomycin B for 4 h.
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The generation of chicken spleen cells transformed
by retroviral vector pMH-v-Rel-IRES-FLAG-vN-
Trip6 has been described previously [7]. Eight milli-
liters of an exponentially growing culture of these
suspension cells were pelleted and cells were then
incubated in 150 Wl of lysis bu¡er (0.2 M NaCl,
50 mM Tris, pH 7.5, 0.2 mM ZnCl2, 0.5% NP-40,
0.5 mM DTT, 10% glycerol, 1% aprotinin (Sigma),
2 Wg/ml leupeptin (Sigma)) on ice for 40 min. Sam-
ples were pelleted at top speed in a microcentrifuge
for 10 min at 4‡C, and the supernatant was then re-
pelleted for 20 min at 4‡C. 120 Wl of supernatant was
incubated with BD bu¡er containing DNA^cellulose,
and beads were washed as described above. Samples
were then boiled in 2USDS sample bu¡er and re-
solved on 12.5% SDS-polyacrylamide gels. Fifteen
microliters of cell lysate supernatant (described
above) was loaded on the gel in parallel as a control.
Western blotting was then performed using either
anti-Rel or anti-FLAG antiserum as a primary anti-
body as described previously [6].
3. Results
3.1. Treatment of cells with leptomycin B causes
Trip6 to accumulate in the nucleus
The Trip6-related proteins zyxin and LPP have
been shown to shuttle between focal adhesion
plaques and the nucleus [4,5]. For this reason, we
were interested in determining whether Trip6, which
is primarily located in adhesion plaques when over-
expressed in CEF [6], also shuttles between cytoplas-
mic and nuclear compartments. Therefore, CEF
transfected with a FLAG-Trip6 expression vector
were treated with leptomycin B, which is an inhibitor
of Crm1-dependent nuclear export [20,21]. The sub-
cellular localization of FLAG-Trip6 was then ana-
lyzed by indirect immuno£uorescence using an anti-
FLAG primary antibody. Consistent with our pre-
vious results [6,7], over-expressed FLAG-Trip6 in
untreated CEF resides primarily in focal adhesion
plaques (Fig. 1A). However, upon treatment of cells
with leptomycin B for as short as 15 min or as long
as 4 h, the majority of FLAG-Trip6 was localized in
the nucleus (Fig. 1B,C). These results suggest that
Trip6 shuttles between cytoplasmic and nuclear com-
partments, and that the movement of Trip6 from the
nucleus to the cytoplasm is dependent on Crm1, as it
is blocked speci¢cally by leptomycin B.
3.2. Trip6 contains a conserved NES between residues
100 and 107
We have previously shown that deletion of the N-
terminal 115 aa of mouse Trip6 causes it to accumu-
late in the nucleus [6,7], suggesting that these sequen-
ces contain a NES. Therefore, we used three ap-
proaches to identify the Trip6 NES. First, deletion
Fig. 2. Trip6 contains a leucine-rich NES between aa 100 and 107. (A) The subcellular localization of the indicated FLAG-tagged de-
letion mutants of Trip6 in transfected CEF was determined by indirect immuno£uorescence using an anti-FLAG primary antiserum
as in Fig. 1. Hatched boxes, LIM domains; numbers indicate Trip6 aa in the protein. (B) Comparison of NES of mouse Trip6 with
other NESs. Essential leucine residues (L) are in larger font. (C) The indicated leucine residues of FLAG-Trip6 were mutated to ala-
nine residues (bold A) and the subcellular location of the indicated protein was determined as in (A). (D) The subcellular localization
of the indicated recombinant v-Rel proteins in CEF was determined by indirect immuno£uorescence using an anti-v-Rel primary anti-
serum. (E) The Trip6 NES is aligned with the analogous sequences in zyxin, LPP, and Ajuba.
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analysis indicated that the Trip6 NES was located
between residues 72 and 115 of mouse Trip6, in
that deletion of these sequences caused nuclear accu-
mulation of Trip6 (Fig. 2A). Second, inspection of
these sequences identi¢ed a leucine-rich sequence
(Fig. 2B), which is characteristic of Crm1-dependent
NESs. Third, conversion of the leucine residues with-
in this putative NES to alanine residues caused
FLAG-Trip6 to accumulate in the nucleus (Fig. 2C).
If these sequences in Trip6 were an independent
NES, we reasoned that they should be able to export
a heterologous protein from the nucleus. For these
experiments we used a mutant of the v-Rel oncopro-
tein (v-dStu/Hinc), which is primarily located in the
nucleus of CEF (Fig. 2D, panel v-dStu/Hinc) [15].
(This deletion mutant of v-Rel was used since it
can conveniently accommodate insertions in the mid-
dle portion of the protein and it does not interact
with cellular proteins that might a¡ect localization
of v-Rel [15].) Insertion of Trip6 aa 76 to 115 in
the middle of the v-dStu/Hinc mutant caused this
v-Rel protein to localize primarily to the cytoplasm
Fig. 3. N- and C-terminal sequences of Trip6 can direct L-gal to the nucleus. Indirect immuno£uorescence (bottom) using an anti-
L-gal primary antiserum of CEF transfected with expression vectors for the Trip6^L-gal fusion proteins shown at the top. The num-
bers above the ¢gures refer to aa from mouse Trip6 included in each protein. Mut, mutant NES.
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(Fig. 2D, panel WT). In contrast, addition of the
same Trip6 sequences containing the mutant NES
or addition of sequences from control protein (L-
gal) did not a¡ect the primarily nuclear localization
of v-dStu-Hinc (Fig. 2D, panels Mut and TGV).
Taken together, the results in this section indicate
that Trip6 has a leucine-rich NES. Notably, this leu-
cine-rich sequence is conserved in the related proteins
zyxin, LPP and Ajuba (Fig. 2E).
3.3. The N- and C-terminal regions of Trip6 have
nuclear targeting functions that can enhance
nuclear accumulation of L-gal
Because Trip6 can enter the nucleus after treat-
ment with leptomycin B and has an NES, we sus-
pected that Trip6 also had sequences that could di-
rect it to the nucleus. To determine whether Trip6
has a nuclear targeting function, we fused either the
N- or C-terminal halves of Trip6 to L-gal and moni-
tored the subcellular localization of the proteins by
indirect immuno£uorescence using an anti-L-gal pri-
mary antibody. L-gal by itself is evenly distributed
between the cytoplasm and the nucleus in CEF
(Fig. 3, panel L-gal). Fusion of the C-terminal half
(aa 280^480) of Trip6 to the C-terminus of L-gal
resulted in a L-gal fusion protein that was located
in the nucleus (Fig. 3, panel L-gal-LIM). This result
indicates that Trip6 aa 280^480, which contain the
three LIM domains, contain a sequence capable of
targeting a heterologous protein to the nucleus.
We also fused sequences in the N-terminal half of
Trip6 (aa 2^282) to the C-terminus of L-gal. This
protein was located exclusively in the cytoplasm
(Fig. 3, panel L-gal-vLIM), consistent with it con-
taining a functional NES as determined above (see
Fig. 2). However, if these N-terminal Trip6 sequen-
ces contained a mutated and non-functional NES,
the L-gal fusion protein was now located in the nu-
cleus. This indicates that the N-terminal region of
Trip6 also contains a nuclear targeting sequence,
whose activity is evident only upon disabling of the
NES.
3.4. Trip6 has multiple transactivation domains
We have previously shown that C-terminal sequen-
ces of mouse or human Trip6, including the LIM
domains, can activate transcription in yeast and
CEF when fused to the GAL4 DNA-binding domain
[6,7]. As shown in Fig. 4A, GAL4 fusion proteins
containing either full-length Trip6 or the related pro-
tein zyxin can also readily activate transcription in
CEF. To map the sequences in Trip6 responsible for
Fig. 4. Trip6 contains multiple transactivation domains. The transcriptional activating ability of the indicated GAL4-fusion proteins
was determined by CAT reporter gene assays in CEF. Fold activation is relative to the level of acetylation seen with GAL4 alone
(1.0). (A) GAL4^Trip6 and GAL4^Zyxin can activate transcription. (B) Transactivation by the indicated Trip6 deletion mutants was
determined. (C) Mutation of the Trip6 NES reduces transactivation by GAL4^Trip6 proteins. (D) Comparison of subcellular location
and transcription activation by Trip6 NES mutants. Subcellular localization was performed by indirect immuno£uorescence on full-
length Trip6 proteins as described for Fig. 2. Transactivation was determined using GAL4-full-length Trip6 fusion proteins as in (C).
(E) Indirect immuno£uorescence using an anti-GAL4 primary antibody of CEF transfected with expression vectors for the indicated
proteins.
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transcription activation, we performed GAL4-site
CAT reporter gene assays in CEF with a series of
GAL4^Trip6 fusion proteins (Fig. 4B). This analysis
shows that sequences from both the N- and C-termi-
nal halves of Trip6 contribute to its transactivation
ability. The deletion mutants indicate that Trip6 con-
tains one transactivation domain in the C-terminal
LIM domain region (aa 280^480) and a second
transactivation domain between residues 72 and
115.
Because the N-terminal transactivation region (aa
72^115) in Trip6 also contains the NES, we wished
to determine whether the NES was functionally dis-
tinct from the transactivation activity. Therefore, we
assayed the ability of the Trip6 NES Leu-to-Ala tri-
ple mutant to activate transcription. As shown in
Fig. 4C, mutation of all Leu residues within the
NES greatly reduced the ability of GAL4^Trip6 fu-
sion proteins to activate transcription (compare full-
length and vN mutants with the corresponding wild-
type Trip6 proteins, Fig. 4C). In addition, single or
double Leu-to-Ala mutations within the NES re-
sulted in both nuclear accumulation and reduced
transactivation (Fig. 4D).
Because the NES mutations altered a function in-
volved in subcellular localization, we were interested
in comparing the subcellular localization of wild-type
and NES mutant GAL4^Trip6 proteins. Wild-type
GAL4^Trip6 shows a primarily cytoplasmic staining
pattern, whereas the NES mutant GAL4^Trip6 pro-
tein is primarily in the nucleus (Fig. 4E). Thus, wild-
type GAL4^Trip6 activates transactivation more
strongly than NES mutant GAL4^Trip6 proteins
even though there is less wild-type GAL4^Trip6 pro-
tein in the nucleus. Taken together, the results in this
section demonstrate that the same Leu-to-Ala muta-
tions that alter the Trip6 NES function reduce trans-
activation, suggesting that the NES and transactiva-
tion sequences of Trip6 within aa 72 and 115
overlap.
3.5. Trip6 does not bind to DNA^cellulose in vitro
Because of the nuclear functions of Trip6 and the
fact that LIM domains are often associated with
DNA-binding proteins [7,9,11] we next determined
whether Trip6 could bind DNA. In these experi-
ments, in vitro-translated Trip6 or Trip6 isolated
from v-Rel-transformed spleen cells was analyzed
for its ability to bind to DNA^cellulose. Because
the binding of the related LIM domain protein
Hic-5 is dependent on zinc [3], zinc was included in
all experiments. As shown in Fig. 5A, in vitro-trans-
lated full-length Trip6 or vN-Trip6 (aa 116^480 of
Trip6) did not bind to DNA^cellulose. As controls in
these experiments, the v-Rel transcription factor did
bind to DNA (last lane in right panel of Fig. 5A),
but a v-Rel mutant (v-dStu/Hinc, see Fig. 2D) that
cannot bind to UB sites and the plasma membrane
protein c-Src did not bind to DNA (Fig. 5A right
panel). Similarly, when isolated from v-Rel-trans-
formed spleen cells, FLAG-vNTrip6 did not bind
Fig. 4 (continued)
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to DNA, whereas v-Rel did (Fig. 5B). These results
indicate that, at least under the conditions used here,
neither full-length Trip6 nor the LIM domain region
of Trip6 can bind to DNA^cellulose.
4. Discussion
In this report, we provide extensive evidence that
LIM domain protein Trip6 shuttles between focal
adhesion plaques and the nucleus. That is, treatment
of cells with leptomycin B, an inhibitor of Crm1-de-
pendent nuclear export, results in nuclear accumula-
tion of Trip6, and Trip6 has an independent NES. In
addition, N- and C-terminal sequences of Trip6, in-
cluding the LIM domains, have a nuclear targeting
signal. Moreover, we show that Trip6 has multiple
transactivation domains, and that mutations that
abolish the NES function also lessen transactivation
by Trip6.
Although Trip6 and the related proteins zyxin and
LPP have all been shown to shuttle between focal
adhesion plaques and the nucleus, these proteins ap-
pear to largely reside in adhesion plaques in the
steady-state [5^7,9]. For example, at any given mo-
ment, very little Trip6 appears in the nucleus in con-
trol cells overexpressing Trip6 (see Fig. 1A). Never-
theless, treatment of CEF with leptomycin B for as
little as 15 min results in an almost exclusively nu-
clear localization of Trip6. One interpretation of
these results is that Trip6 is very rapidly exported
from the nucleus once it enters it. Alternatively, the
focal adhesion plaque localization of Trip6 is depen-
dent on a leptomycin B sensitive function or protein,
Fig. 5. In vitro- and in vivo-synthesized Trip6 does not bind to DNA^cellulose. (A) The indicated proteins were translated in vitro in
the presence of Tran35S-label (Input) and were incubated with DNA^cellulose (Bound) as described in Section 2.3. Samples were then
detected by molecular imaging. The input lanes have approximately 1/3 to 1/5 the amount of protein as in the bound lanes. (B) Ly-
sates from chicken spleen cells transformed with an expression vector for v-Rel and FLAG-vN-Trip6 (lanes 2 and 3 in each panel)
were analyzed directly (Input) or were incubated with DNA^cellulose (Bound). Western blotting was performed with anti-v-Rel antise-
rum (left panel) or anti-FLAG antiserum (right panel). In each case, the respective in vitro-translated proteins (IVT) were used as size
controls.
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which, when inhibited, causes Trip6 to rapidly enter
the nucleus.
Our results identify the Trip6 NES as being part of
a leucine-rich sequence from aa 100 to 107, which is
analogous to the NESs that were identi¢ed in LPP
and Ajuba [5,8]. Curiously, a di¡erent leucine-rich
sequence was identi¢ed as an NES in the highly re-
lated protein zyxin [4], even though both leucine-rich
sequences are highly related in Trip6, LPP and zyxin
[6]. Our identi¢cation of the Trip6 NES is unambig-
uous: that is, deletion or mutation of this sequence
sequesters Trip6 in the nucleus and this NES can
independently export a heterologous protein (v-Rel)
from the nucleus (Fig. 2). Moreover, deletion of the
zyxin-like NES from Trip6 does not alter its focal
adhesion plaques localization (Wang and Gilmore,
unpublished results). Thus, the reason for the di¡er-
ence in function of these leucine-rich NESs between
Trip6 and LPP versus zyxin is not clear.
We have also shown that sequences of Trip6, in-
cluding the LIM domains, can direct cytoplasmic
L-gal to the nucleus. Inspection of the Trip6 sequen-
ces reveals no obvious consensus (basic) nuclear tar-
geting sequence [22]. Thus, either Trip6 has an un-
conventional nuclear localization sequence or, for
example, the LIM domains interact with a protein
that brings these sequences to the nucleus. Of note,
armadillo repeat domains, also protein^protein inter-
action domains, have been shown to participate di-
rectly in nuclear localization of L-catenin [23,24] and
possibly the APC tumor suppressor protein [25].
Our results have also identi¢ed (at least) two trans-
activation domains in Trip6: one between aa 72 and
115 and one including the C-terminal LIM domains.
The transactivation domain between 72 and 115 ap-
pears to overlap with the Trip6 NES in that Leu-to-
Ala mutations that abolish the nuclear export func-
tion also greatly lessen the transactivation function.
Alternatively, nuclear export of Trip6 is required for
a nearby transactivation domain to function maxi-
mally. In either case, to our knowledge, this is the
¢rst identi¢cation of an NES that is part of or re-
quired for a transactivation domain.
It is still not clear what relevance nuclear localiza-
tion or transactivation has for the function of Trip6.
In that we have shown that Trip6 does not bind to
DNA^cellulose (Fig. 5), it appears unlikely that
Trip6 functions as a direct activator of transcription.
We have previously shown that a nuclear-localized
form of Trip6 can act as a co-activator for the v-
Rel transcription factor [7]. In addition, Trip6 can
interact with thyroid hormone receptor, a nuclear
localized sterol receptor, in a hormone-dependent
manner [11]. Of note, JAB1, which was originally
identi¢ed as a co-activator of the c-Jun transcription
factor, is co-localized with integrin LFA-1 at the cell
membrane, but upon activation of LFA-1 a fraction
of JAB1 enters the nucleus [26].
However, no cellular signal has been identi¢ed that
can induce nuclear localization of Trip6, nor the re-
lated proteins zyxin, LPP, or Ajuba. For example,
activation of focal adhesion kinase (FAK) by v-Src
does not induce nuclear translocation of Trip6 nor
does treatment of cells with cytochalasin D, an actin
¢lament disrupting reagent, or okadaic acid, a Ser/
Thr phosphatase inhibitor, induce its nuclear trans-
location (Wang and Gilmore, unpublished results).
Although zyxin, Trip6, LPP, Ajuba, and Hic-5 are
highly related LIM domain proteins, which largely
reside in adhesion plaques but can enter the nucleus
and can activate transcription, these proteins clearly
have di¡erences. For example, although Ajuba can
enter the nucleus, it appears to be largely cytosolic [8]
rather than localized in adhesion plaques like other
members of this family. Similarly, although Hic-5
has been shown to bind to DNA [3], the other mem-
bers of this family have not. As described above, the
sequences that act as NESs for zyxin and Trip6 may
di¡er. Furthermore, although zyxin and LPP have
been shown to bind to the VASP/Ena protein
[5,10], which is likely to be involved in the regulation
of cell migration [27], Trip6 does not appear to have
a VASP-Ena binding domain. Lastly, nuclear-local-
ized Ajuba and Trip6 proteins can promote embry-
onic carcinoma cell di¡erentiation, but zyxin cannot
[8]. Taken together, these results indicate that these
related LIM domain proteins have distinct functions.
It will be of interest to determine the e¡ect of dis-
ruption of the genes encoding these proteins in mice
and the e¡ect of their overexpression in tissue culture
cells.
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